PAC Dermatologia-1 Libro 2
Contenido
REFERENCIAS

Dermatofitosis
  1. Fitzpatrick : Dermatology in General Medicine: 1999. 5th Edition, Vol II Superficial Fungal Infection: Dermatophytosis, Tinea Nigra, Piedra: Chapter 206: 2.337-2.357.

  2. Arenas R. Micología Médica Ilustrada Dermatofitosis, México. Interamericana-McGraw-Hill 1993 : 57 – 75.

  3. Aly R. Ecology and Epidemiology of Dermatophyte Infections. J Am Acad Dermatol 1994, Vol 31 (3 pt 2): 21 – 25

  4. Macura A. Dermatophyte Infections. Int J Dermatol 1993; 32 (5): 313 – 323.

  5. Dahl M. Clinical Inmunodermatology. 3rd ed. St Louis: Mosby, 1996.

  6. Jones H.E. Inmune Response and Host Resistance in Humans to Dermatophyte Infection. J Am Acad Dermatol 1993; 28:12 –18.

  7. Fafutis M.M, Guillen Vargas C. Respuesta Inmunitaria en las Micosis Dermatología Rev. Mex 1999; 43:54 – 61.

  8. Zaias N, Rebeilg, Int J Dermatol 1996;35 (9) :614 –17.

  9. Warren N: Taxonomy and Introduction Dermatologic Clinics 1996;14 (1):1-7.

  10. Weitzman J, Padhye A. Gross Dermatophyte and Microscopic. Dermatologic Clinics 1996;14 (1):9 – 22.

  11. López MR. Méndez Tovar LJ. Técnicas de Diagnóstico en Micología Cutánea Dermatología Rev Mex 1999;43: 541- 547

  12. Asawanonda P. Wood’s Light in Dermatology Int J Dermatol 1999; 38: 801-807.

  13. Babel D. How Identify Fung. J Am Acad Dermatol 1994; 31 (3 part 2):108-111.

  14. Fridling M. Dermatophytosis of the Feet. Dermatol Clin 1996; 14 (1): 33 – 40.

  15. Leyden J.L, Tinea Pedis: Pathophysiology and Treatment. J Am Acad Dermatol 1994; 31 (3 pt 2):31 – 33.

  16. Daniel III C, Gupta A, et al. Two Feet–One Hand Syndrome: A Retrospective Muilticenter Survey. Int J Dermatol 1997; 36: 658–660.

  17. Leyva J. Méndez P, Arenas R. Pie de Atleta. Datos Actuales sobre su causa en la Ciudad de México. Dermatología Rev Mex 1998; 42 (2):58 – 62.

  18. Midgley G, Moore MK, Cook JC et al. Micology of Nail Disorders J Am Acad Dermatol 1994;31 (3 pt 2): 68–74.

  19. Arenas R, Ocejo D. Dermatología Rev Mex 1997; 41 (5):171– 75.

  20. Muñoz – Hink H, Leyva J, Arenas R. Onicomicosis,. Su Frecuencia en Pacientes con Psoriasis. Dermatología Rev Mex 1999; 43 (2): 41– 5.

  21. Del Angel W, Arce M, Arenas R et al. Detección de Micosis Podales y Portadores en Pacientes Diabéticos Ambulatorios, Dermatología Rev Mex 1997; 41 (6):216– 22.

  22. Vázquez del Mercad E, Arenas R. Epidemiología y Causas de la Tiña del Cuerpo. Dermatología Rev Mex 1999; 43 (6):260–63.

  23. García A, Silvestri G, et al. Micosis más Frecuentes en Pediatría, Análisis de 2,227 casos. Dermatología Rev Mex 1999; 43:6 – 9.

  24. Elewski B. Tinea Capitis. Dermatol Clin 1996;14 (1):23–31.

  25. Frieden I, Howard R, Tinea Capitis : Epidemiology, Diagnosis, Treatment and Control. J Am Acad Dermatol 1994; 31 (3 pt2):42– 46.

  26. Mayorga J, Gómez R, Parra I, García A, Tiña de la Cabeza. Dermatología Rev Mex 1999; 43 (6): 264–7.

  27. Krafchik B, Pelletier J. An open study of tinea capitis in 50 children treated with a 2-week course of oral terbinafine. J Am Acad Dermatol 1999; 41:60-3.

  28. Conant M. The Aids Epidemic. J Am. Acad Dermatol 1994;31 (3 pt 2):47–5.

  29. Conant M. Fungal Infections in Inmunocompromised individual. Dermatol Clin 1996; 14 (1):155–162.

  30. Odom R. Common Superficial Fungal Infections in Inmunosupressed Patients, J Am Acad Dermatol 1994;31 (3 pt2):56–59.

  31. Dechauvin MF, Dubertretl. Infection a Dermatophytes et Pathologie A VIH. J Med Mycol1995; 5(Supl 1):8 –10.

  32. Chang P. Onicopatias en Pacientes con SIDA. Dermatología Rev Mex 1998; 42 (3):91–94.

  33. Pierard GE, Arrese JE, Pierard-Franchimont C. Treatment and prophylaxis of tinea infections. Drugs 1996;52(2):209-24.

  34. Abdel-Rahman SM, Nahata MC, Powel DA. Response to initial griseofulvin therapy in pediatric patients with tinea capitis. Ann Pharmacother 1997;31(4):406-10.

  35. Abdel-Rahman S, Powell DA, Nahata MC. Efficacy of itraconazole in children with Trichophyton tonsurans tinea capitis, J Am Acad Dermatol 1998;38:443-6.

  36. Degreef H, Itraconazole in the treatment of tinea capitis. Cutis 1996;58(1):90-3.

  37. Solomon B, Collins R, Sharma R, Silverberg N et al. Fluconazole for the treatment of tinea capitis in children. J Am Acad Dermatol 1997;37:274-5.

  38. Mercurio MG, Silverman RA, Elewski BE, Tinea capitis: fluconazole in Trichophyton tonsurans infection. Pediatr Dermatol 1998;37(6):450-3.

  39. Haroon TS, Hussain I, Aman S, et al. A randomized double-blind comparative study of terbinafine for 1,2 and 4 weeks in tinea capitis. Br J Dermatol 1996;135(1)86-88.

  40. Gruseck E, Splanemann V, Bleck O, et al. Oral terbinafine in tinea capitis in children. Mycoses 1996;39(5-6):237-40.

  41. Bruckbauer HR, Hofmann H. Systemic antifungal treatment of children with terbinafine. Dermatology 1997; 195(2):134-6.

  42. Rademaker M, Havill S, Griseofulvin and terbinafine in the treatment of tinea capitis in children. NZ Med J 1998;111(1060):55-7.

  43. Greer D, Weiss J, Rodriguez D, et al. A randomized trial to asses once-daily topical treatment of tinea corporis with butenafine, a new antifungal agent. J Am Acad Dermatol 1997; 37:231-5.

  44. Evans EG, Seaman RA, James IG. Short-duration therapy with terbinafine 1% cream in dermatophyte skin infections Br J Dermatol 1994;130(1):83-7.

  45. Savin RC, Treatment of chronic tinea pedis (athletes foot type) with topical terbinafine. J Am Acad Dermatol 1990;23(4 pt2):786-9.

  46. Berman B, Ellis C, Leyden J et al. Efficacy of a 1-week twice daily regimen of terbinafine 1% cream in the treatmen of interdigital tinea pedis. Results of placebo-controlled, double-blind, multicenter trials. J Am Acad Dermatol 1992;26(6):956-60 46. Bakos L, Brito AC, Castro LC et al. Open clinical study of the efficacy and safety of terbinafine cream 1% in children with tinea corporis and tinea cruris. Pediatr Infect Dis J 1997; 16(6)545-8.

  47. Barnetson RS, Marley J, Bullen M et al. Comparison of one week of oral terbinafine (250 mg/d) with four weeks of treatment with clotrimazole 1% cream. Br J Dermatol 1998;139 (4):675-8.

  48. Tanuma H, Nishiyama S. Clinical evaluation of bifonazole for moccasin-type tinea pedis. Mycoses 1997;40(5-6):223-8.

  49. Yamaguchi H, Uchida K, Watanabe S et al. Preclinical and clinical studies of the efficacy of bifonazole in patients with tinea pedis at 10 years after approval. Part 1. Susceptibility to bifonazole of clinical isolates of dermatophytes. Jpn J Antib 1996;49 (12):1085-94.

  50. Beierdorffer H, Michel G, Kehr K. Croconazole in the treatment of tinea pedis. Mycoses 1995;38(11-12):501-7.

  51. Lozoya X, Navarro V, García M, Zunta M. Solarium chrysotrichum (Schldl.) a plant used in Mexico for the treatment of skin mycosis. J Ethnopharmacol 1992;36(2):127-32.

  52. Boonk W, de Geer D, de Keek E et al. Itraconazole in the treatment of tinea corporis and tinea cruris: comparison of two treatment schedules. Mycoses 1998;41(11-12):509-14.

  53. Stary A, Sarnow E. Fluconazole in the treatment of tinea corporis and tinea cruris. Dermatology 1998;196 (2):237-41.

  54. Tuzun Y, Kotogyan A, Oguz O. Terbinafine: efficacy and safety in the treatment of dermatophytosis. Int J Dermatol 1992;31(10):720-1.

  55. Zaias N, Glick B, Rebell G. Diagnosing and treating onychomycosis. J Fam Pract 1996;43(4):330.

  56. Seebacher C. Limits of brief treatment of onychomycoses. Hautarzt. 1998;49 (9):705-8.

  57. De Doncker PD, Gupta AK, Marynissen G, et al. Itraconazole pulse therapy for onychomycosis and dermatomycoses: an overview. J Am Acad Dermatol 1997;37(6):969-74.

  58. Roberts DT. Oral terbinafine (Lamisil) in the treatment of fungal infections of the skin and nails. Dermatology 1997;194 (suppl 1):37-9

  59. Faergemann J, Laufen H. Levels of fluconazole in normal and diseased nails during and after treatment of onychomycoses in toe-nails with fluconazole 150 mg once weekcly. Acta Derm Venereol 1996;76(3):219-21.

  60. Craig A. Elmets. Management of common superficial fungal infections in patients with AIDS. J Am Acad Dermatol 1994;31:S60-S63.


Candidosis
  1. Odds FC. Candida and Candidosis , 2nd ed, 1988. London, Bailliere-Tindall.

  2. Bonifaz A. Candidosis, EN: Micología Médica Básica. Ed. Méndez, México D.F. 1990, pp: 277-301

  3. Delgado V, Crespo, V. Aspectos clínicos de las candidosis cutánomucosas. Monografías de Dermatología. 1993; 7:102-113.

  4. Ree SE, Mayer KH. Opportunistic candidal infections in patients infected with human immunodeficiency virus. Clin. Infect. Dis 1995; 21:99-102.

  5. Samonis G, Skrodilis P, Marak S, et al. Oropharingeal candidiasis as a maker for esophangeal candidiasis in patients with cancer. Clin Infect Dis 1998; 27:283-286.

  6. Eisen D, Lynch DP. Fungal infections. In: The Mouth. Diagnosis and treatment. De. Mosby, St. Louis Missouri 1998, pp: 128-144.

  7. Lynch LP. Oral candidiasis. History, classification and clinical presentation. Oral Surg, Oral Med, Oral Pathol 1995, 78:189-93.

  8. Colligon PJ, Sorell TC. (1983): Diseminated candidiasis: evidence of a distinctive syndrome in heroin abusers. Br.Med.J. 287:861-862.

  9. Daniel r, Gupta A, Daniel PM, et al. Candida infection of the nail: Role as a primary or secondary pathogen. Int J. Dermatol 1998; 37 :904-7.

  10. Manzano-Gayoso P, Méndez-Tovar LJ, et al. Onicomicosis causada por Candida parapsilosis. ¿Agente ocasional o frecuente? Dermatología Rev. Mex 1998; 42:105-107.

  11. Drohuet E. Candidosis mucocutánea crónica. En: Tratado de Dermatología pediátrica. Ruiz-Maldonado R, et al. Ed. Interamericana MacGraw-Hill, México D.F.1992, pp: 571-584.

  12. Sobel J. Epidemology and pathogenesis of recurrent vulvovaginal candidiasis. Am.J. Obstet. Gynecol 1985; 152:924-935.

  13. Mayorga J, Rodríguez F, Serrato DC, et al. Estudio epidemiológico de candidosis vaginal. Dermatología Rev. Mex 1999, 43: 13-16.

  14. Benitez-Macias MA; García Flores R. Estudio micológico de 180 casos de candidosis vulvovaginal. Tesis, 1999, Fac. Química, UNAM.

  15. Wingard JR. Importance of Candida species other than Candida albicans as pathogens in oncology patients. Clin. Infect. Dis 1995; 115-122.

  16. Odds FC, Bernaert R. CHROMagar-Candida a new differencial isolation medium for presuntive identification of clinical importance Candida species. J. Clin. Microbiol 1994; 32:1923-1929.

  17. Bonifaz A, Araiza SJ, De-Pablo P. CHROMagar-Candida. Experiencia en la identificación presuntiva de levaduras oportunistas aisladas de candidosis oral en pacientes inmunosuprimidos. Bioquimia 1998; 23: 794-800.

  18. Araj GF. Diagnostic value of the enzymelinked immunosorbent assay for detection of C. albicans antigen in sera of cancer patients. J Clin Microbiol 1992; 2.

  19. Bonifaz A, Saúl A. Profilaxis contra Candida sp con suspensión de nistatina en pacientes seropositivos al virus de la inmunodeiciencia humana. Re. Med. Hosp. Gral. Mex 1995; 60: 113-117.

  20. Owen JL, Tate JM. (1998). Management of neonatal candidiasis. Neonatal study group. Pediatr Infect Dis. J 1998; 28:1007-1011

  21. Thomas CJ. Triazole therapy for mucocutaneous candidiasis en HIV-infected patients. J. Assoc Nurses AIDScare 1998; 6:40-44

  22. Smith KJ Warnock CT. Azole resistance in Candida albicans. J. Med. Veter. Mycol 1986; 3:143-4.

  23. Warnock DN, Burke J. Fluconazole resistance in Candida glabrata. Lancet 1988; 2:1310.

  24. Boker DJ, Swidells S, Rinaldi MG. Fluconazole-resistance Candida albicans. Clin. Infect. Dis 1993;, 17: 1018-1021.


Pitiriasis versicolor
  1. Ingham E. Cunninham C. Malassezia furfur. J. Med. Veter. Mycol 1993; 31:265-288.

  2. Silva-Lizama E. Tinea versicolor. Int. J. Dermatol 1995; 34:611-617.

  3. Sunenshine PJ, Schartz RA, Janninger CK. Tina versicolor: an update. Dermatology Pediatr 1998; 61:65-68

  4. Faergemann J. Pityrosporum infections. J. Am. Acad. Dermatol 1994; 31:S18-S20.

  5. Faergemann J, Frederikson,T. Some new aspects on etiology, pathogenesis and treatment. J. Invest. Dermatol 1982; 21:8-11.

  6. Carbajosa J, Vega-Memije E, Alvarez-Paque L., et al. ¿Cuál es la relación de Pityrosporum ovale con la papilomatosis reticulada y confluente de Gougerot y Carteaud? Dermatología Rev. Mex 1995; 39:265-267.

  7. Terragni L, Lasagni A, Oriani A, et. al. Pityriasis versicolor in pediatric-age. Pediatric Dermatol 1995; 74:260-261.

  8. Guého E, Midgley G., Guillot J. The genus Malassezia with description of four new species. Antonien Van Leeuwenhoek 1996; 69:337-355.

  9. Aspiroz MC, Moreno LA, Rubio MC. Taxonomía de Malassezia furfur: Estado en cuestión. Rev Iberoam Micol 1997; 14:147-9.

  10. Vermer BJ, Staats CC. The efficacy of a topical application of terbinafine 1% solution in subjects with pityriasis versicolor. Dermatology 1997; 194 Suppl 1:22-24.

  11. Faergemann J. Treatment of Pityrosporum infections. Dermatol Therapy 1997; 3:22-25.


Micetoma
  1. Godfrey J. Diseases of the foot not hitherto described. Lancet 1846, 1: 593-594.

  2. Mahgoub ES, Murray IG. Mycetoma. William Heinemann: London 1973, 76-115.

  3. Carter HV. On a new striking form of fungus disease principally affecting the foot and prevailing endemically in many parts of India. Tans Med Phys Soc Bombay 1860, 6: 104-142.

  4. Carter HV. On Mycetoma or the Fungus Disease of India. J&A Churchill: London 1874.

  5. Pinoy E. Actinomycoses and mycetomes. Bull Inst Pasteur 1913, 11: 929-938.

  6. Mahgoub ES. Mycoses of the Sudan. Trans R Soc Trop Med Hug 1977, 71: 184-188.

  7. Bout G, Lavalle P, Mariat F, et al. Etude epidemiologic des mycétomes au Mexique a propos de 502 cas. Bull Soc Pathol Exot Filiales 1987, 80: 329-339.

  8. López MR, Mendez TR, Lavalle P, Welsh O, Saul A, Macotela RE. Epidemiología del micetoma en México: Estudio de 2105 casos. Gac Med Mex 1992, 128: 477-481.

  9. Serrano JA, Beaman B, Mejía MA, Viloría JE, Zamora R. The actinomycetoma in Venezuela: A 10-year study (1976-1986). Rev Inst Med Top Sao Paulo 1988, 30: 297-304.

  10. Andleigh HS. Mycetoma foot. Indian J Dermatol 1966, 11: 45-47.

  11. Rey M. les mycétomes dans l’ ouest Africain (medical thesis). Foulon, Paris 1961.

  12. Hay RJ. Agents of eumycotic mycetomas in to play. Wilson’s microbiology and microbial infections Vol. 4, Ajello L and Hay RJ, editora Oxford University Press Inc, New York, 1998: 488-96.

  13. Destombes P. Structure histologique des mycetomes. Ann Soc Belge Med Trop 1964, 44: 897-908.

  14. Hay RJ, Mackenzie DWR. The histopathological features of pale grain eumycetoma. Trans R Soc Trop Med Hyg 1982, 76: 839-844.

  15. Latapí F, Das Mycetom. Die Pilzkrankheiten der Haut durch Helen. Schimmel Aktinomyceten and Verwan die Erreger. Hunbuch der Haut and Gechlechskrankheiten. Jadassohn IV/4. Deutschland. Springer-Verlag. 1963:463.

  16. Arenas R. Dermatología. Atlas, diagnóstico y tratamiento. Segunda edición. MacGraw-Hill Interamericana. México. 1996.

  17. Welsh O, Salinas MC, Rodríguez MA. treatment of eumycetoma and actinomycetoma in current topics in medical mycology. Borgers M, Hay RJ, Rinaldi MG, eds. Prous science Philadelphia. 1995; 47-71.

  18. Vera-Cabrera L, Rodríguez-Quintanilla MA, Boiron P, Salinas-Carmona MC, Welsh O. Experimental mycetoma by Nocardia Brasiliensis in rats. J. mycol. Med. 1998; 8: 183-87.

  19. González Ochoa A, Shibayama H, Félix D, Anaya M. Immunological aspects of actinomycotic mycetoma and nocardiosis. Excerpta Medica Int. Ceny ser. 1961; 55: 542-51.

  20. Salinas MC, Torres E, Ramos AI, Licón-Trillo A, González-Spencer D. Immuny response to Nocardia brasiliensis antigens in an experimental model of actinomycetomas in BALB/cmice. Mayo 1999. Vol. 67. 5: 2428-2432.

  21. Salinas MC, Vera L, Welsh O, Rodríguez M. Antibody response to Nocardia brasiliensis antigens in man. Zbl Bakt 1992, 276: 390-397.

  22. Vera LC, Salinas MC, Welsh O, Rodríguez M. Isolation and purification of two immunodominat antigens from Nocardia brasiliensis. J Clin Microbiol 1992, 30: 1183-1188.

  23. Salinas MC, Casillas S, Welsh O, An ELISA for serological diagnosis of Nocardia brasiliensis in clinical correlation of mycetoma infection J Clin Micribiol 1993, 31: 2901-2906.

  24. Welsh O. Mycetoma current concepts in treatment. Int J Dermatol 1991, 30: 387-398.

  25. Saúl A, Bonifaz A, López M. amoxicilin and clavulanic acid in the treatment of actinomycetoma. Int J Derm 1993, 23: 218-220.

  26. Welsh O, Salinas MC, Rodríguez M. Mycetoma in infections diseases, fifth edition. Hoeprich PD, Jordan MC, Ronald AR, eds. J.B. Lippincott Co. Philadelphia. 1994.

Esporotricosis
  1. Lavalle, P. Esporotricosis. Simposium “Desarrollo y Estado Actual de la Micología Médica en México”. Memorias Simposium Syntex. Marzo de 1980

  2. Mayorga R. Prevalence of subcutaneus Mycosis in Latin America. Proc. I Internat. Sym. On Mycosis . Washington D.C. 1970 PAHO Sc. Pub. 1970; N° 205 pp 18-27

  3. Shenck RB. On refractory subcutaneous abscesses cauised by a fungus possebly related to sporotrichia. Bull Johns Hopkins Hosp; 1898;9:286-90

  4. Beurman de L. y Gougerot, H. Les Sporotrichoses. Félix Alcan., edit. París, 1912

  5. González BJ. La esporotricosis enfermedad ocupacional de los alfareros. Rev, Hosp.:Universit (Monterrey), 1952;2:215-232

  6. Padilla C. Laboratorio de Micología. Rev Centro Dermat. Pascua. 1997;6 (3):182-185

  7. Aceves OR. Epidemiología de las micosis profundas en Jalisco. Mem. V Cong. Mex. Dermatol. 1970; 256-269

  8. Mayorga J., Tarango V. y Barbarubio J. Esporotricosis cien años después. Dermatología Rev. Mex. 1999;43(suplemento):22-29

  9. Latapí F. Esporotricosis facial infantile. Prensa Med. Mex. 1950;15: 259

  10. Valle Meza JA y Barba M. Esporotricosis facial en un lactante. Mem. I Cong. Mex. Derm:, 1963;273-275

  11. Mackinnon JE. Conti Díaz et al. Isolation of Sporothrix schenckiii from nature. Sabouradia 1969;7:38-45

  12. Lavalle P. & Mariat F. Sporotricosis. Bull. Inst. Pasteur, 1983-1981,295.

  13. Lavalle P. Esporotricosis en México. Algunas peculiaridades clínicas y síntesis patogénica. Mem. III Cong. Iber. Lat. Amer. Derm. , México, D.F. 1959, pp 190-197

  14. Lavalle P. Novales J. y Mariat F. Esporotricosis: nuevas observaciones clínicas, histopatológicas y micológicas. Mem I Cong. Mex. Derm. 1963;pp 276-287

  15. Serstock D. & Zinnerman H.: Pulmonary and articular sporotrichosis. Report of two cases. JAMA. 1975,233, 1291-1293.

  16. Rippon JW. Esporotricosis en Tratado de micología medica. Hongos y actinomicetos patógenos. Editorial Interamericana. McGraw Hill 1ª edición 1990 pp 351-380

  17. Mariat F, & Lavalle P. Sporotrichosis. Quaderni di cooperazione sanitaria. Human Mycoses in tropical Countries, 2nd. Edition 1991;13: 107:118

  18. González Ochoa y Soto Figueroa. Polisacáridos de Sporotrix schenckii. Rev. Inst. Salub. Y Enfer. Trop. Mex. 1947;8:143-153

  19. Kaplan W. & González Ochoa A. Aplication of the fluorescent antibody technique to the rapid diagnosis of sporotrichosis J, Lab. Clin. Med. 1963; 62:835

  20. Buot G., Lavalle P. et Mariat F. Sporotrichose. Encyclopedie medico Chirurgicale (Paris) 1993. 8-604-A-10.

  21. Mariat F, & Lavalle P. y Destombes P. Recherches sur la Sporotrichose Etude Mycologique et pouvoir pathogene de Souches Mexicaines de Sporotrichum scenckii. Sabouradia 1962;2:60-79

  22. Novales J. Navarrete G. Ramos A. Esporotricosis. Aspectos histológicos, análisis de 50 casos. Rev Cent. Dermat. Pascua 1995;4(3):149-152

  23. al-Tawfig J A., Wools K K. Diseminated sporotrichosis and Sporothrix schesnckii fungemia as the initial presentation of human immunodeficiency virus infection. Clin. Infect Dis. 1998.26(6):1403-6.

  24. Lavalle P. Aspectos clínicos, inmunológicos y epidemiológicos de la esporotricosis. Mem. IV Congreso Mexicano de Dermatología, Tampíco, Tam. México, 1968. pp 5-18.

  25. Miranda RN. Esporotricose e Esporotriquina Separata. Prensa Médica (Lisboa) 1960;24:1-4

  26. MacKinnon J.E. Conti Díaz. Influencia de las condiciones ambientales sobre la esporotricosis. Actas finales V Cong. Iber. Lat. AMER. Derm: Buenos Aires 1963:287.290

  27. Watanabe S. Local Heat Treatment of Sporotrichosis by Pocket Warmer “Kairo” VI Congress of International Society of Human and Animal Mycology Tokio, Japón. Abstracts 1975:9

  28. Meneghini CL., Angelini E, Bonifazi E. y Liospal Luti M. Clinical and Inmunological aspects of sporotrichosis cutánea. Contact Dermatitis 1978;4:33-40

  29. Peñaloza J A., Lavalle P., Cardoso A. y Zamacona P. Esporotricosis cutánea y articular. Estudio de un caso tratado con yoduro de potasio y sulfametoxazol-trimetoprim. Dermatología Rev. Mex. 1980,24:190-199.

  30. Lavalle P. Suchil P. De Ovando F. y Reynoso S. Itraconazole for Deep Mycoses: Preliminary Experience in México. Reviews of Infectious Diseases 1987;9(supp 1):S64-S70.

  31. Ramírez J., Byrd R P. Jr. and Roy Tom. Chronic cavitary pulmonary sporotrichosis: Efficacy of oral itraconazole. Jky Med. Assoc, 1998;96 (3):103-5.

  32. Restrepo A. Treatment of topical Mycosis. J. Am: Acad. Dermatol. 1994:31(3):S91-S102.

  33. Díaz M. Negroni R, Montero-Gei F. et al. A Pan American 5 year study of fluconazole therapy for deep mycoses in the inmunocompetent host. Clin Infect Dis 1992;14(supl 1):S68-76.

  34. Hull PR. Vismer HF. Potential use of Terbinafine in the Treatment of Cutaneous Sporotrichosis. Rev. Contemp. Pharmacother. 1997;8:343-347.

LECTURAS RECOMENDADAS
  1. Arenas R. Micología Médica Ilustrada. 1a. ed. Edit. McGraw-Hill, 1993, México, D.F.

  2. Bonifaz A. Micología Médica Básica. Méndez editores, 1990, México D.F.

  3. Jacobs PH, Nall L. Antifungal Drug Therapy. 1st ed. Edit. Marcel Dekker, inc.1990, New York, USA.

  4. Known-Chung KJ, Bennett JE. Medical Mycology. 1st ed. Edit. Lea & Febiger. 1992, Philadelphia USA.

  5. López-Martínez R, Méndez-Tovar LJ, Hernández-Hernández F, Castañón-Olivares R. Micología Médica. Procedimientos para el diagnóstico de laboratorio. 1ª de. Edit. Trillas, 1995, México D.F.

  6. Rippon J. Medical Mycology. The pathogenic fungi and the pathogenic actinomycetes. 3a. ed. W.B. Saunders, Co. 1988, Philadelphia,

  7. Saúl A. Lecciones de Dermatología. 10a. ed. Editorial Méndez-Cervantes. 1983, México, D.F.
Contenido
Copyright © 2000 Dr. Scope. Derechos Reservados.
Diseño y Programación: Educación Médica Contínua